A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Table 2 Change from baseline to Week 12 in monthly acute headache medication days and migraine related disability and productivity as measured by the modified migraine disability assessment (mMIDAS)

	n		Adjusted mean change (SE)		Comparison of adjusted means Test vs Ref
	Erenumab	Placebo	Erenumab	Placebo	Difference (Test-Ref.)	SE	95% CI	Two-sided P-value
Monthly acute headache medication days	270	274	− 5.34 (0.39)	− 4.66 (0.39)	− 0.67	0.55	(− 1.76, 0.41)	0.223
mMIDAS score	263	268	− 14.67 (1.20)	− 12.93 (1.19)	− 1.74	1.69	(− 5.06, 1.58)	0.305

The P-values reported for the secondary endpoints (monthly acute headache medication days and mMIDAS) are nominal and should be interpreted with caution
The secondary efficacy endpoints (change from baseline in monthly acute headache medication days and mMIDAS) were analysed using a generalised linear mixed effects repeated measures model similar to the primary endpoint
CI, confidence interval; mMIDAS, modified migraine disability assessment; SE, standard error
n Number of patients with non-missing value at the corresponding time point of interest

ISSN: 1129-2377